175 related articles for article (PubMed ID: 38422701)
1. Recent advances and mechanisms of action of PD-L1 degraders as potential therapeutic agents.
Zhang F; Jiang R; Sun S; Wu C; Yu Q; Awadasseid A; Wang J; Zhang W
Eur J Med Chem; 2024 Mar; 268():116267. PubMed ID: 38422701
[TBL] [Abstract][Full Text] [Related]
2. Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy.
Feng C; Zhang L; Chang X; Qin D; Zhang T
Front Immunol; 2023; 14():1230135. PubMed ID: 37554324
[TBL] [Abstract][Full Text] [Related]
3. [Regulation of PD-L1 posttranslational modification and its application progress in tumor immunotherapy].
Su Y; Wang Q; Ru Y; Dong J; Li X; Zhang Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Nov; 38(11):1036-1043. PubMed ID: 36328434
[TBL] [Abstract][Full Text] [Related]
4. Post-translational regulations of PD-L1 and PD-1: Mechanisms and opportunities for combined immunotherapy.
Dai X; Gao Y; Wei W
Semin Cancer Biol; 2022 Oct; 85():246-252. PubMed ID: 33831533
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumour potential of PD-L1/PD-1 post-translational modifications.
Zhou S; Zhu J; Xu J; Gu B; Zhao Q; Luo C; Gao Z; Chin YE; Cheng X
Immunology; 2022 Dec; 167(4):471-481. PubMed ID: 36065492
[TBL] [Abstract][Full Text] [Related]
6. Generation, secretion and degradation of cancer immunotherapy target PD-L1.
Shen DD; Bi YP; Pang JR; Zhao LJ; Zhao LF; Gao Y; Wang B; Liu HM; Liu Y; Wang N; Zheng YC; Liu HM
Cell Mol Life Sci; 2022 Jul; 79(8):413. PubMed ID: 35819633
[TBL] [Abstract][Full Text] [Related]
7. Targeting the PD-L1 cytoplasmic domain and its regulatory pathways to enhance cancer immunotherapy.
Chai F; Li P; Liu X; Zhou Z; Ren H
J Mol Cell Biol; 2024 Apr; 15(11):. PubMed ID: 37993416
[TBL] [Abstract][Full Text] [Related]
8. Post-translational Modification of PD-1: Potential Targets for Cancer Immunotherapy.
Lee TA; Tsai EY; Liu SH; Hsu Hung SD; Chang SJ; Chao CH; Lai YJ; Yamaguchi H; Li CW
Cancer Res; 2024 Mar; 84(6):800-807. PubMed ID: 38231470
[TBL] [Abstract][Full Text] [Related]
9. Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy.
Hsu JM; Li CW; Lai YJ; Hung MC
Cancer Res; 2018 Nov; 78(22):6349-6353. PubMed ID: 30442814
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 degradation pathway and immunotherapy for cancer.
Gou Q; Dong C; Xu H; Khan B; Jin J; Liu Q; Shi J; Hou Y
Cell Death Dis; 2020 Nov; 11(11):955. PubMed ID: 33159034
[TBL] [Abstract][Full Text] [Related]
11. PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy.
Ren X; Wang L; Liu L; Liu J
Front Immunol; 2024; 15():1392546. PubMed ID: 38638430
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition.
Wu Y; Chen W; Xu ZP; Gu W
Front Immunol; 2019; 10():2022. PubMed ID: 31507611
[TBL] [Abstract][Full Text] [Related]
13. Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy.
Hu X; Wang J; Chu M; Liu Y; Wang ZW; Zhu X
Mol Ther; 2021 Mar; 29(3):908-919. PubMed ID: 33388422
[TBL] [Abstract][Full Text] [Related]
14. The role of exosomal PD-L1 in tumor progression and immunotherapy.
Xie F; Xu M; Lu J; Mao L; Wang S
Mol Cancer; 2019 Oct; 18(1):146. PubMed ID: 31647023
[TBL] [Abstract][Full Text] [Related]
15. Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation.
Shi C; Wang Y; Wu M; Chen Y; Liu F; Shen Z; Wang Y; Xie S; Shen Y; Sang L; Zhang Z; Gao Z; Yang L; Qu L; Yang Z; He X; Guo Y; Pan C; Che J; Ju H; Liu J; Cai Z; Yan Q; Yu L; Wang L; Dong X; Xu P; Shao J; Liu Y; Li X; Wang W; Zhou R; Zhou T; Lin A
Nat Commun; 2022 Nov; 13(1):6951. PubMed ID: 36376293
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics.
Yamaguchi H; Hsu JM; Yang WH; Hung MC
Nat Rev Clin Oncol; 2022 May; 19(5):287-305. PubMed ID: 35132224
[TBL] [Abstract][Full Text] [Related]
17. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
Wang Z; Wu X
Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
[TBL] [Abstract][Full Text] [Related]
18. Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy.
Ayala-Mar S; Donoso-Quezada J; González-Valdez J
J Immunol Res; 2021; 2021():8839978. PubMed ID: 33628854
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms Controlling PD-L1 Expression in Cancer.
Cha JH; Chan LC; Li CW; Hsu JL; Hung MC
Mol Cell; 2019 Nov; 76(3):359-370. PubMed ID: 31668929
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of new dihydropyridine derivatives as PD-L1 degraders for enhancing antitumor immunity.
Pan C; Luo M; Lu Y; Pan X; Chen X; Ding L; Che J; He Q; Dong X
Bioorg Chem; 2022 Aug; 125():105820. PubMed ID: 35569191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
